A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors

A Phase I/II Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of HB0028 in Patients With Advanced Solid Tumors

It is a phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.

Study Overview

• Status: Recruiting
• Conditions: Cervical Cancer; Advanced Solid Tumor
• Intervention / Treatment: Drug: HB0028

Detailed Description

This is a phase I/II, multicenter, open-label, first-in-human study in patients with advanced solid tumors. During the phase I study, the safety and tolerability of HB0028 will be evaluated in patients with advanced solid tumors. In the phase II study, the safety and efficacy of HB0028 at the RP2D will be evaluated in cohorts of patients with specific solid tumors.

• Study Type: Interventional
• Enrollment (Estimated): 54
• Phase: Phase 2; Phase 1

Contacts and Locations

• Study Contact: Name: Yuan Tang, Bachelor; Phone Number: 6617 021-51320053; Email: yuan.tang@huaota.com
• Study Contact Backup: Name: Kexin Hou, Master; Phone Number: 6033 021-51320053; Email: kexin.hou@huaota.com

Study Locations

• China
  • Hunan
    • Changsha, Hunan, China, 410013
      • Recruiting
      • Hunan Cancer Hospital
      • Contact: Jing Wang, MD/PHD; Phone Number: 0731-88651900; Email: wangjing0081@126.com
      • Contact: Yan Tang, MD/PHD; Phone Number: 0731-88651900; Email: tangyan6049@hnca.org.cn
      • Principal Investigator: Jing Wang, MD/PHD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients must meet all the following criteria to be eligible for participation in this study:

  1. Male or female. Age ≥ 18 years.
  2. The subject is able to understand and willing to sign the Informed Consent Form(ICF); willing and able to comply with all study procedures.

  3. a) dose escalation: Patients with histologically or cytologically confirmed locally advanced, recurrent, or metastatic solid tumors (or clinically diagnosed hepatocellular carcinoma) that failed all standard therapies known to provide clinical benefit; [These solid tumors include but not limit to: non-small cell lung cancer, esophageal squamous cell carcinoma, melanoma, head and neck squamous cell carcinomas, hepatocellular carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, etc.].

     b) dose expansion (Cervical cancer group): Histologically confirmed persistent, recurrent, or metastatic ([International Federation of Gynecology and Obstetrics(FIGO)] stage IVB) cervical cancer that is not eligible for curative surgery and/or definitive concurrent radiotherapy; The pathological type was squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma.; According to the investigator's judgment, it may benefit from the study drug treatment; patients with disease progression after at least one previous systemic therapy (such as systemic chemotherapy).

  4. At least one measurable tumor lesion was present according to RECIST 1.1. A baseline imaging assessment could be performed up to 28 days before the first dose.
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1.
  6. Life expectancy ≥12 weeks

  7. liver function requirements:

     1. Total bilirubin (TBIL) ≤ 1.5×ULN
     2. Aspartate aminotransferase(AST) and Alanine aminotransferase(ALT) ≤ 2.5×ULN; AST or ALT ≤5×ULN if liver metastases are present;
  8. Creatinine (Scr) < 1.5×ULN and Calculated creatinine clearance (CrCL) > 50 mL/ min (Cockroft-Gault Equation);
  9. Hematology absolute neutrophil count (ANC) ≥ 1.5×109/L; hemoglobin (HGB) ≥ 90 g/L ；platelets (PLT) ≥ 75×109/L;
  10. Coagulation function: International Normalized Ratio(INR)≤ 1.5×ULN; Prothrombin Time(PT)≤ 1.5×ULN; Activated Partial Thromboplastin Time(APTT)≤ 1.5×ULN. No active or clinically significant bleeding within 14 days before the first dose.
  11. Recovery to Grade 0-1 from adverse events (AEs) related to prior anticancer therapy except alopecia, < Grade 2 sensory neuropathy, and endocrinopathies controlled with hormone replacement therapy
  12. Women of childbearing potential must confirm a negative serum or urine pregnancy test within 3 days prior to the initiation of study treatment; Fertile patients and their partners must agree to use effective contraceptives for the duration of study drug use and for 90 days after the last administration of study treatment.

Exclusion Criteria:

• Exclusion Criteria Patients are excluded from the study if any of the following criteria apply:

  1. Have clinically active central nervous system (CNS) metastases. Patients with previously-treated brain or meningeal metastases may participate and be eligible for treatment provided they are stable (>4 weeks) and asymptomatic. Patients with asymptomatic brain metastasis or subjects who are symptomatically stable after treatment and are on < 10 mg/d prednisone or equivalent are eligible.
  2. dose expansion (Cervical cancer group): Hydronephrosis, which could not be relieved by clinical treatment
  3. Active autoimmune disease or history of autoimmune disease requiring systemic therapy < 2 years prior to screening except hypothyroidism, vitiligo, Grave's disease, Hashimoto's disease, or Type I diabetes. Patients with childhood asthma or atopy that has not been active in the 2 years prior to study screening are eligible.
  4. History of Grade 3-4 immune-related adverse events (irAEs) or irAEs requiring discontinuation of prior therapies, (except for grade 3 endocrinopathy that is managed with hormone replacement therapy).
  5. Use of systemic corticosteroids in a dose equivalent to >10 mg/day of prednisone or other immunosuppressive agent < 2 weeks prior to screening; the use of topical, intraocular, intraarticular, intranasal, or inhaled corticosteroids and systemic steroids to prevent (e.g., allergy to contrast agents) or treat non-autoimmune condition (e.g., delayed hypersensitivity caused by exposure to allergens) or short course (< 5 days) will be allowed
  6. Cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial infarction (MI), unstable angina, or New York Heart Association (NYHA) class III or IV heart failure < 6 months of study entry; uncontrolled arrhythmia < 3 months of study entry; mean ECG QT-interval corrected according to Fridericia's formula (QTcF) > 470 milliseconds (ms) obtained from three ECGs;
  7. uncontrolled diabetes, glycosylated hemoglobin HbA1c >8%；
  8. Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter) prior to study entry; palliative radiotherapy to a single area < 2 weeks prior to study screening is permitted. Measurable lesions cannot be previously irradiated unless they have demonstrated growth after radiation therapy (According to RECIST v1.1).
  9. Patients who have previously received allogeneic stem cell, Bone marrow or solid organ transplantation.

  10. The following infections are present

      1. Active infection requiring intravenous treatment within 2 weeks before screening
      2. Active Pulmonary tuberculosis
      3. Positive results for HIV test
      4. Active hepatitis B or C. Patients with asymptomatic hepatitis B virus carriers (HBV DNA titer < 1000 cps/mL or 200 IU/mL) or cured hepatitis C virus(HCV)(negative HCV RNA test) may be enrolled;
  11. Major surgery < 4 weeks prior to the first dose; Minor surgery < 2 weeks prior to the first dose
  12. History of severe allergic reactions, grade 3-4 allergic reactions to treatment with another monoclonal antibody, or known to be allergic to protein drugs or recombinant proteins or excipients in HB0028 drug formulation;
  13. Have received or will receive a live vaccine within 30 days prior to the screening.
  14. Patients who have participated in any clinical trial of a drug or medical device within 30 days prior to the first dose
  15. Any other serious underlying medical condition (e.g., active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, cardiac conditions), or psychiatric, psychological, familial condition or geographical location that, in the judgment of the Investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment.
  16. Positive COVID-19 quantitative real time (qRT) polymerase chain reaction (PCR) or rapid screening test during screening;
  17. Patients with a history of arterial or deep vein thrombosis within 6 months before enrollment; evidence or history of a bleeding tendency within 2 months before enrollment
  18. Severe dyspnea, pulmonary insufficiency or the need for continuous supportive oxygen therapy
  19. The surgical site, the wound site, the mucous membrane severely ulcerated, or the fracture did not heal completely
  20. Conditions that may cause bleeding or perforation of the digestive tract (such as duodenal ulcer, intestinal obstruction, Crohn's disease, Ulcerative colitis, large gastrectomy and small bowel resection, etc.); Patients with a history of intestinal perforation and fistula, who were not cured after surgical treatment; Esophageal and gastric varices
  21. Immunomodulatory therapy was administered within 2 weeks before enrollment (including but not limited to cyclosporine and tacrolimus)
  22. Have history of interstitial lung disease or non-infectious pneumonitis, except from radiotherapy (the enrollment of subjects needs to be considered after discussion with MM);
  23. Other conditions which would make it inappropriate for the patient to participate as judged by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: HB0028; HB0028 IV every 3 weeks (q3w)	Drug: HB0028; Patients will be assigned to dose regimens in the order of enrollment, and they will receive their assigned fixed dose of HB0028 via intravenous infusion. HB0028 IV every 3 weeks (q3w).; Other Names: Anti-PD-L1 and TGF-β bifunctional fusion protein

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety and tolerability	Number of participants with a Dose Limiting Toxicity(DLT)[Time Frame:During the first days]DLTs will be assessed during the first 21 days of treatment for dose-escalation phase and are defined as toxicities that meet pre-defined severity criteria,and assessed as having a suspected or definite relationship to study drug.	Up to 12 Months
Maximun Tolerated Dose(MTD)	MTD or Optimal Biological Dose(OBD) and/or RP2D.	Up to 24 Months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC	AUC Area Under concentration-time Curve (AUC)	Up to 24 Months
Cmax	Maximum serum concentration(Cmax)	Up to 24 Months
Tmax	Half-life time of maximum concentration	Up to 24 Months
ORR	Overall response rate(ORR) as measured by RECIST v1.1.	Up to 24 Months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of the lymphocyte subpopulations.	The percentage of lymphocyte subpopulations of the peripheral blood will be assessed by flow cytometry.	Up to 24 Months
Programmed death ligand 1(PDL1) expression level	The expression of PD-L1 in tumor tissues was detected by immunohistochemical method.	Up to 24 Months
Tubuloglomerular Feedback(TGF-β)	Levels of TGF-β1, TGF-β2, TGF-β3 in plasma	Up to 24 Months

Collaborators and Investigators

• Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd.
• Investigators: Principal Investigator: Jing Wang, MD/PHD, Hunan Cancer Hospital

Study record dates

Study Major Dates

• Study Start (Actual): September 9, 2022
• Primary Completion (Estimated): May 1, 2024
• Study Completion (Estimated): October 1, 2024

Study Registration Dates

• First Submitted: December 24, 2023
• First Submitted That Met QC Criteria: January 15, 2024
• First Posted (Estimated): January 25, 2024

Study Record Updates

• Last Update Posted (Estimated): January 25, 2024
• Last Update Submitted That Met QC Criteria: January 15, 2024
• Last Verified: January 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Uterine Neoplasms; Genital Neoplasms, Female; Uterine Cervical Diseases; Uterine Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases; Genital Diseases, Female; Uterine Cervical Neoplasms
• Other Study ID Numbers: HB0028-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No